2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hörl, W. H. Search for Related Content PubMed PubMed Citation Articles by Hörl, W. H.

Hemodialysis Membranes: Interleukins, Biocompatibility, and Middle Molecules

Department of Medicine, Division of Nephrology, University of Vienna, Vienna, Austria.

Correspondence to Dr. Walter H. Hörl, Department of Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Phone: +43-1-40400-4390; Fax: +43-1-40400-4392; E-mail: walter.hoerl{at}nephro.imed3.akh-wien.ac.at

Abstract

ABSTRACT. Maintenance hemodialysis patients display evidence of elevated interleukin-1 (IL-1) and tumor necrosis factor alpha release after stimulation either by contaminated dialysate, bioincompatible membrane material, or both. This release is followed by the stimulated secretion of a large number of other interleukins, particularly IL-6, the cytokine principally responsible for acute-phase protein synthesis. It has been shown that high levels of the circulating proinflammatory cytokines IL-1, tumor necrosis factor alpha, IL-6, and IL-13 are associated with mortality in hemodialysis patients. Essential functions of polymorphonuclear leukocytes—that is, phagocytosis, oxygen species production, upregulation of specific cell surface receptor proteins, or apoptosis—are disturbed in patients with end-stage renal disease. These are further altered as a result of complement activation by the hemodialysis procedure, particularly if bioincompatible dialyzers are used. Polymorphonuclear leukocyte degranulation occurring during extracorporeal circulation does not depend on complement activation but rather on intracellular calcium and the presence or absence of the degranulation inhibitory proteins angiogenin and complement factor D. Clinical signs and symptoms of end-stage renal disease patients are at least in part related to the accumulation of middle molecules such as ß₂-microglobulin, parathyroid hormone, advanced glycation end products, advanced lipoxidation end products, advanced oxidation protein products (formed as a result of oxidative stress, carbonyl stress, or both), granulocyte inhibitory proteins, or leptin. Currently available membrane materials do not provide long-lasting, effective reduction of middle molecules in patients who require maintenance hemodialysis.

This article has been cited by other articles:

				M. D. Navarro, J. Carracedo, R. Ramirez, J. A. Madueno, A. Merino, M. Rodriguez, A. Martin-Malo, and P. Aljama Bacterial DNA prolongs the survival of inflamed mononuclear cells in haemodialysis patients Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3580 - 3585. [Abstract] [Full Text] [PDF]

				H. Koller, K. Hochegger, G. J. Zlabinger, K. Lhotta, G. Mayer, and A. R. Rosenkranz Apoptosis of human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation of the complement system Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3104 - 3111. [Abstract] [Full Text] [PDF]

				E. J. Mullin, M. S. Metcalfe, and G. J. Maddern Artificial Liver Support: Potential to Retard Regeneration? Arch Surg, June 1, 2004; 139(6): 670 - 677. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673